Medicine & Life Sciences
Acute Myeloid Leukemia
100%
Myelodysplastic Syndromes
53%
Survival
52%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
51%
Cytarabine
46%
Philadelphia Chromosome
41%
Clofarabine
35%
Decitabine
35%
Inotuzumab Ozogamicin
29%
blinatumomab
27%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
26%
Therapeutics
26%
Recurrence
25%
Frailty
24%
ponatinib
21%
Azacitidine
20%
Leukemia, Myelomonocytic, Chronic
20%
Idarubicin
20%
B-Cell Chronic Lymphocytic Leukemia
20%
Drug Therapy
18%
venetoclax
18%
Residual Neoplasm
17%
PCI 32765
17%
Leukemia
16%
Neoplasms
16%
Clinical Trials
16%
Random Allocation
16%
GATA2 Deficiency
16%
Vincristine
15%
Breast Neoplasms
15%
Biomarkers
14%
Progression-Free Survival
13%
Proportional Hazards Models
13%
Salvage Therapy
13%
Doxorubicin
13%
Cyclophosphamide
12%
Sarcoma
12%
Rituximab
12%
Cytogenetics
11%
Protein-Tyrosine Kinases
11%
Mammography
11%
Survival Analysis
11%
fludarabine
10%
Flow Cytometry
10%
Allogeneic Cells
10%
Dexamethasone
10%
Bone Marrow
9%
Dasatinib
9%
Joints
9%
Machine Learning
8%
Mathematics
Biomarkers
33%
Recurrent Events
27%
Frailty Model
24%
Clinical Trials
22%
Prediction
20%
Covariates
19%
Randomisation
17%
Survival Data
17%
Functional Principal Component Analysis
17%
Joint Model
16%
Simulation Study
15%
Leukemia
15%
Design
15%
Soft Tissue
14%
Cancer
14%
Competing Risks
14%
Model
13%
Longitudinal Data
12%
Censoring
12%
Breast Cancer
10%
Regression
10%
Frailty
10%
Recurrence
9%
Transformation Model
9%
Progression
9%
Linear Transformation Model
9%
Landmarks
9%
Trajectory
9%
Proportion
9%
Tumor
8%
Real-time
8%
Polymerase Chain Reaction
8%
Evaluate
8%
Survival Time
8%
Informative Censoring
7%
Regression Analysis
7%
Semiparametric Model
7%
Demonstrate
7%
Gaussian Quadrature
7%
Therapy
6%
Estimate
6%
Cure Model
6%
Non-proportional Hazards
6%
Quantile
6%
Predict
6%
Proportional Hazards Model
6%
Mixture Model
6%
Dependent
6%
Treatment Effects
6%
Performance
6%